Compare AdaptHealth Corp (AHCO) vs Carvana Co (CVNA) Price & Performance

AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.

The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.

Carvana (CVNA) trades at $72.01, down 2.95% today, as investors digest recent earnings and guidance. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, CVNA delivered impressive Q2 2026 results with revenue up 52% to $7.38 billion and record retail unit growth of 38%, though full-year EBITDA guidance of $2.70–$3.0 billion disappointed some investors.

While Carvana demonstrates robust revenue growth and improving profitability, its premium valuation (P/E 38.1, EV/EBITDA 575.03) and execution risks warrant caution. The company's debt reduction from 89.99% to 41.12% debt-to-asset ratio since 2022 is positive, but competitive pressures and margin compression remain key concerns. Analyst consensus suggests 21% upside to the $87.18 price target.